Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
Australia
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Drugs in Development
Details:
Laronidase is a Enzyme drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Mucopolysaccharidosis I.
Lead Product(s): alpha L Idosiduronase,Inapplicable
Therapeutic Area: Genetic Disease Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Enzyme
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 26, 2021
Lead Product(s) : alpha L Idosiduronase,Inapplicable
Therapeutic Area : Genetic Disease
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
China Post-marketing Surveillance (PMS) Study of Aldurazyme®
Details : Laronidase is a Enzyme drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Mucopolysaccharidosis I.
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
November 26, 2021
Details:
Laronidase is a Enzyme drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Mucopolysaccharidosis I.
Lead Product(s): alpha L Idosiduronase,Inapplicable
Therapeutic Area: Genetic Disease Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Enzyme
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 09, 2024
Lead Product(s) : alpha L Idosiduronase,Inapplicable
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy and Safety of YW17 (Laronidase-CinnaGen) Compared to Aldurazyme® in MPS I Patients
Details : Laronidase is a Enzyme drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Mucopolysaccharidosis I.
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
May 09, 2024
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
Global Sales Information
ABOUT THIS PAGE
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
